Company: SUPN
Filing Date: 2025-05-06
Form Type: 10-Q
Source: 0001356576-25-000033
Chunk: 34

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-05-06
Form: 10-Q
Item: Part I, Item 1
Chunk 34
---
 $138,461 Royalty, licensing and other revenues7,836 5,183 Total revenues149,824 143,644 Costs and expensesCost of goods sold(a)15,763 16,309 Research and development26,927 24,930 Selling, general and administrative89,944 86,516 Amortization of intangible assets19,786 20,137 Contingent consideration loss (gain)7,660 (1,095)Total costs and expenses160,080 146,797 Operating loss(10,256)(3,153)Other income (expense)Interest and other income, net4,425 3,396 Total other income (expense), net4,425 3,396 Earnings (loss) before income taxes(5,831)243 Income tax expense5,996 119 Net earnings (loss)$(11,827)$124 Earnings (Loss) per shareBasic$(0.21)$0.00 Diluted$(0.21)$0.00 Weighted average shares outstandingBasic55,864,692 54,801,748 Diluted55,864,692 55,626,663 _____________________________

(a) Excludes amortization of acquired intangible assets

See accompanying notes.

4

Table of Contents

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Comprehensive Earnings (Loss)

(in thousands)

Three Months EndedMarch 31,20252024(unaudited)Net earnings (loss)$(11,827)$124 Other comprehensive gainUnrealized gain on marketable securities, net of tax30 59 Other comprehensive gain30 59 Comprehensive earnings (loss)$(11,797)$183 

See accompanying notes.

5

Supernus Pharmaceuticals, Inc.

Condensed Consolidated Statements of Changes in Stockholders’ Equity 

(unaudited, in thousands, except share data)

jCommon StockAdditional Paid-in CapitalAccumulated OtherComprehensiveEarnings (Loss)RetainedEarningsTotalStockholders’EquitySharesAmountBalance, December 31, 202455,743,095 $56 $479,440 $(189)$556,426 $1,035,733 Share-based compensation expense related to employee stock purchase plan and share-based awards— — 8,068 — — 8,